Letrozole (Femara) for Estrogen Management — Testosterone & Androgens
Most potent non-steroidal aromatase inhibitor, used off-label for estradiol control and in fertility protocols.
Overview
Letrozole is the most potent third-generation non-steroidal aromatase inhibitor, capable of suppressing estradiol levels by over 97-99% at standard oncologic doses. It reversibly binds to the heme group of the aromatase enzyme CYP19A1 with approximately 170-fold greater potency than anastrozole in vitro. FDA-approved for breast cancer treatment, letrozole has significant off-label applications in both fertility medicine and hormone management during TRT. In reproductive endocrinology, letrozole is widely used for ovulation induction and is considered first-line therapy for anovulatory infertility in PCOS by ACOG. In men on TRT, letrozole's extreme potency requires careful dose titration — even 1.25-2.5 mg weekly can drastically reduce estradiol. Over-suppression is a significant risk, leading to joint pain, decreased libido, fatigue, and bone loss. Due to this narrow therapeutic window in the TRT context, many clinicians prefer anastrozole for routine estrogen management, reserving letrozole for refractory cases or specific fertility protocols.
Indications
- FDA-approved: Adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women
- FDA-approved: Extended adjuvant treatment after 5 years of tamoxifen
- FDA-approved: First-line treatment of advanced breast cancer
- Off-label: Ovulation induction in PCOS (first-line per ACOG)
- Off-label: Estradiol management during TRT (use with caution — very potent)
- Off-label: Male infertility
Mechanism of Action
Letrozole binds reversibly to the aromatase enzyme heme group with approximately 170-fold greater affinity than anastrozole
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Letrozole | 1.25 mg | Once weekly | Conservative starting dose for TRT estrogen management |
| Letrozole | 2.5 mg | Once weekly | Standard TRT dose — monitor closely for over-suppression |
| Letrozole | 2.5 mg | Once daily | FDA-approved breast cancer dosing — not appropriate for TRT |
| Letrozole | 2.5-7.5 mg | Daily x 5 days (CD3-7) | Ovulation induction protocol for PCOS/infertility |
Evidence Grade
GRADE B
Safety & Contraindications
- Extreme potency — high risk of estradiol over-suppression in men
- Significant bone mineral density loss with chronic use (up to 6-8% decrease in 2 years in breast cancer trials)
- Arthralgia, myalgia, and hot flashes are very common
- Adverse lipid changes more pronounced than other AIs at equivalent suppression
- Category X in pregnancy — potent teratogen
- Drug interactions: CYP3A4 and CYP2A6 substrates